Merck delays filing for combo cholesterol drug
672526
Merck & Co. MRK.N said on Friday it   would delay seeking approval for a combination pill designed to   lower "bad" cholesterol, increase "good" cholesterol and avoid   a common side effect of one of the ingredients.
578766
The company announces another slight delay with its lead drug.
458999
Merck & Co.  said on Friday it  would delay seeking approval for a combination pill designed to  lower "bad" cholesterol, increase "good" cholesterol and avoid  a common side effect of one of the ingredients.
102166
U.S. regulators on Friday delayed a  decision on whether to approve over-the-counter sales of a Barr  Pharmaceuticals "morning-after pill" to prevent pregnancy,  prompting a lawsuit from a women's rights group.
261717
Novartis AG, Switzerland&#39;s largest drugmaker, said the US Food and Drug Administration has delayed approval of its Certican transplant treatment and is seeking more information on safe and effective dosing.
597705
SILVER SPRING, Maryland  - A U.S. advisory panel urged the government on Thursday to reject Merck & Co Inc's latest bid to sell a cholesterol-lowering drug without a prescription.
721591
Merck &amp; Co., Inc., knew of problems with its blockbuster painkiller Vioxx long before the drug was pulled from the market in September due to newer studies that linked the medication to an increased risk of heart attack and stroke, the Wall Street Journal
769773
TRENTON, N.J. -- Shares of drug maker Merck &amp; Co. dropped 2.5 percent in heavy trading yesterday, a day after medical journal reports offered fresh ammunition to patients suing over its withdrawn painkiller Vioxx.
498617
TORONTO - The hearing into insider trading allegations leveled against the chairman of ATI Technologies has been pushed back until March 29.
443819
U.S. regulators have asked for more data  on Novartis AG's  diabetes drug Galvus, possibly  delaying approval of the potential blockbuster by a year, which  dented its shares while boosting its main rival's.
310914
NEW YORK, December 8  - Merck &amp; Co (MRK.NYS) has guided to lower-than-expected 2005 earnings due to the withdrawal of its blockbuster arthritis drug, Vioxx, and increased generic competition for its cholesterol drug, Zocor.
379753
Merck & Co.  expects to seek U.S. approval in 2007 for drugs to treat HIV, cholesterol and insomnia, and aims to have another four products in late-stage trials by midyear, the company said on Tuesday.
173242
MONTPELIER, Vt. The Food and Drug Administration has postponed its response to Vermont&#39;s first-in-the-nation lawsuit over the importation of prescription drugs from Canada.
597746
Industry analysts are predicting US regulators this month will refuse to approve Merck &amp; Co.&#39;s new arthritis drug until at least 2006 because of heart attacks linked to its recalled sister drug Vioxx.
339141
Merck can&#39;t expect any immediate relief from the medicine that was supposed to replace Vioxx, the pain medication it took off the market.
280625
U.S. regulators said on Friday they would review whether to take action over Merck & Co Inc's and Schering-Plough Corp's popular cholesterol medicine Vytorin after a study showed it was no better than a generic drug in preventing the build-up of fatty plaque.
316389
MERCK faces a fresh barrage of lawsuits over its Vioxx arthritis drug that together could cost it as much as $18 billion (Â£9.8 billion) as hundreds of lawyers from across America will next week team up for a combined attack on the embattled drug